{"id":53109,"date":"2023-01-19T17:02:50","date_gmt":"2023-01-19T16:02:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-real-world-evidence-solutions-market-report-to-2031-players-include-clinigen-cognizant-technology-solutions-clarivate-and-ibm-researchandmarkets-com\/"},"modified":"2023-01-19T17:02:50","modified_gmt":"2023-01-19T16:02:50","slug":"global-real-world-evidence-solutions-market-report-to-2031-players-include-clinigen-cognizant-technology-solutions-clarivate-and-ibm-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-real-world-evidence-solutions-market-report-to-2031-players-include-clinigen-cognizant-technology-solutions-clarivate-and-ibm-researchandmarkets-com\/","title":{"rendered":"Global Real World Evidence Solutions Market Report to 2031 – Players Include Clinigen, Cognizant Technology Solutions, Clarivate and IBM – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Real World Evidence Solutions Market By Components, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global real-world evidence solutions market was valued at $1,369.3 million in 2021, and is projected to reach $4,993.24 million by 2031, registering a CAGR of 13.7% from 2022 to 2031.\n<\/p>\n

\nReal-world evidence is defined as the healthcare data derived from a variety of non-traditional clinical research settings, such as electronic medical records (EMRs), claims and billing information, product and disease registries, and information collected by mobile devices and health apps.\n<\/p>\n

\nThe four main sources of collecting real-time data are administrative\/claims data, clinical data, patient-generated or reported data, and emerging data sources including social media and cross-industry data collaborations such as Project Data Sphere. It is most commonly used by pharmaceutical companies, payers, and providers to better manage their organizations and make decisions about cost-effectiveness and comparative efficacy where other more robust data sources do not exist.\n<\/p>\n

\nThe key factors that drive the growth of the market are increase in the prevalence of cancer and chronic diseases, which increase the demand for the development of novel drugs and medical devices across the world.\n<\/p>\n

\nIn addition, rise in adoption of technological advanced real-world evidence solutions; and increase in number of pipeline drugs are the key factors that further boost the growth of market. Moreover, rise in R&D activity rates, government initiatives, improved healthcare infrastructure, and increased funding for research projects across the world further propel the growth of the market.\n<\/p>\n

\nIn addition, increase in number of key players and the strategies adopted by them, and rise in demand for technologically advanced medical devices to conduct real time surveys and clinical trials propel the growth of the real-world evidence solutions market.\n<\/p>\n

\nHowever, lack of awareness and reluctance to rely on real-world data hamper the market growth. Furthermore, high growth potential in developing economies and growth in focus on end-to-end real-world evidence services are expected to provide lucrative opportunity for the growth of real-world evidence solutions market during the forecast period.\n<\/p>\n

\nKey Benefits For Stakeholders<\/strong>\n<\/p>\n